A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Patients with cancers of the head and neck never treated in the metastatic setting will be randomized to receive chemotherapy with or without Bevacizumab (Avastin).